Related Experiment Video
Updated: Jun 2, 2026
Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
Treatment of gastrointestinal stromal tumor after imatinib and sunitinib
Michael Montemurro1, Sebastian Bauer
1Comprehensive Cancer Center, University Hospital Lausanne (CHUV), Lausanne, Switzerland. michael.montemurro@chuv.ch
Purpose Of Review:
Tyrosine kinase inhibitors (TKIs), such as imatinib and sunitinib, have changed the outcome of patients with gastrointestinal stromal tumor (GIST) and prolonged survival by many-fold. Unfortunately, treatment failure and tumor progression seem inevitable over time and constitute an unresolved clinical challenge. This article reviews current efforts to overcome drug resistance and progression.
Recent Findings:
The major mechanism of resistance toward imatinib and sunitinib is the development of secondary resistance mutations in the kinase domain of KIT. Recent efforts aim at inhibitors with increased activity against resistance mutations or a broader spectrum of activity. Other strategies include indirect KIT inhibition by modulating KIT chaperone proteins or inhibition of KIT-dependent and independent signaling pathways.
Summary:
The rapid improvement of our understanding of GIST biology as well as resistance mechanisms towards imatinib and sunitinib will greatly facilitate the development of novel treatment strategies. This article summarizes the results of recently reported third and fourth-line clinical trials in patients with resistant GIST and reviews data of important proof-of-concept studies.
Insights
Tyrosine kinase inhibitors (TKIs) improve outcomes for gastrointestinal stromal tumor (GIST) patients, but resistance is common. Novel strategies target resistance mutations and signaling pathways to overcome treatment failure in GIST.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Tyrosine kinase inhibitors (TKIs) like imatinib and sunitinib have significantly improved survival for gastrointestinal stromal tumor (GIST) patients.
- Treatment failure and tumor progression remain significant challenges in GIST management due to drug resistance.
Purpose of the Study:
- To review current strategies aimed at overcoming drug resistance and tumor progression in GIST.
- To summarize recent clinical trial data and proof-of-concept studies for resistant GIST.
Main Methods:
- Review of current literature on GIST resistance mechanisms.
- Analysis of data from third and fourth-line clinical trials in resistant GIST patients.
- Evaluation of novel therapeutic approaches targeting KIT and its pathways.
Main Results:
- Secondary resistance mutations in the KIT kinase domain are a major mechanism of resistance to imatinib and sunitinib.
- Emerging strategies include developing TKIs with broader activity against resistance mutations.
- Alternative approaches involve indirect KIT inhibition and targeting downstream signaling pathways.
Conclusions:
- Advances in understanding GIST biology and resistance mechanisms are driving the development of new treatments.
- Novel therapeutic strategies hold promise for improving outcomes in patients with resistant GIST.
- Continued research into resistance mechanisms and targeted therapies is crucial for advancing GIST treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:15Drugs that Stabilize Microtubules